Pressure BioSciences (OTCQB: PBIO), a leader in the
development and sale of high pressure-based instruments, consumables, and
related services for the global life sciences industry, this morning announced
worldwide publication by independent researchers of more than 20 scientific
papers in 2018 citing advantages of the company’s pressure cycling technology
(“PCT”) platform. The publications, authored by scientists from industry,
government and academia (a number of which are key opinion leaders in their
field) provided a wide range of applications for PBIO’s patented PCT Platform
in cancer research, biomarker discovery, food safety, and proteomic and
molecular biology studies. “We know that scientists have a strong tendency to
rely heavily on data and opinions from colleagues and other experts in their
field,” PBIO’s Global Director of Sales and Marketing Roxana McCloskey stated
in the news release. “We therefore enhanced our marketing efforts during the
second half of 2018 with a concerted effort to forward this large number of
scientific publications to our base of existing and potential customers. We
were pleased to see this effort result in increased interest and sales of our
Barocycler instruments in 2018, which we believe will continue into 2019 as
well.”
To view the full press release, visit http://ibn.fm/yqyer
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life sciences industry. PBIO’s products are based on the
unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions (e.g., cell lysis, biomolecule extraction).
The company’s primary focus is in the development of high pressure-based
products for biomarker and target discovery, drug design and development,
biotherapeutics characterization and quality control, food science, soil &
plant biology, forensics, and counter-bioterror applications. Additionally,
PBIO is actively expanding the use of its pressure-based technologies in the
following areas: (1) the use of its recently acquired protein disaggregation
and refolding technology from BaroFold, Inc. to allow entry into the biologics
manufacturing and contract research services sector, and (2) the use of its
recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology
(“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible
fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized,
extended shelf-life or room temperature stable low-acid liquid foods that
cannot be effectively preserved using existing non-thermal technologies.For
more information, visit the company’s website at www.PressureBiosciences.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
